News
ALGS
5.58
+0.09%
0.01
Weekly Report: what happened at ALGS last week (0615-0619)?
Weekly Report · 3d ago
Weekly Report: what happened at ALGS last week (0608-0612)?
Weekly Report · 06/15 09:37
Weekly Report: what happened at ALGS last week (0601-0605)?
Weekly Report · 06/08 09:35
Analysts Offer Insights on Healthcare Companies: Veeva Systems (VEEV) and Aligos Therapeutics (ALGS)
TipRanks · 06/04 01:30
Analysts Are Bullish on Top Healthcare Stocks: Aligos Therapeutics (ALGS), Jade Biosciences (JBIO)
TipRanks · 06/01 14:30
Weekly Report: what happened at ALGS last week (0525-0529)?
Weekly Report · 06/01 09:37
Aligos Therapeutics (ALGS) Gets a Buy from Cantor Fitzgerald
TipRanks · 05/29 13:26
Aligos Therapeutics Price Target Announced at $45.00/Share by Lake Street
Dow Jones · 05/28 17:28
Lake Street Initiates Coverage On Aligos Therapeutics with Buy Rating, Announces Price Target of $45
Benzinga · 05/28 17:18
Analysts’ Top Healthcare Picks: Aligos Therapeutics (ALGS), Equillium (EQ)
TipRanks · 05/28 14:40
Aligos Therapeutics initiated with a Buy at Lake Street
TipRanks · 05/28 13:28
Aligos Presents Promising Data For Pevifoscovir Sodium In Treating Hepatitis B
NASDAQ · 05/27 12:47
Aligos says Phase 1 follow-up data for pevifoscorvir sodium suggest reduction in HBV cccDNA reservoir
PUBT · 05/27 06:31
Aligos Therapeutics Presents Positive Data at the EASL Congress 2026
Barchart · 05/27 01:30
Weekly Report: what happened at ALGS last week (0518-0522)?
Weekly Report · 05/25 09:38
H.C. Wainwright Remains a Buy on Aligos Therapeutics (ALGS)
TipRanks · 05/22 10:35
Aligos Therapeutics Price Target Announced at $20.00/Share by Cantor Fitzgerald
Dow Jones · 05/21 14:24
Aligos Therapeutics Initiated at Overweight by Cantor Fitzgerald
Dow Jones · 05/21 14:24
Cantor Fitzgerald Initiates Coverage On Aligos Therapeutics with Overweight Rating, Announces Price Target of $20
Benzinga · 05/21 14:14
Aligos Therapeutics initiated with an Overweight at Cantor Fitzgerald
TipRanks · 05/21 11:02
More
Webull provides a variety of real-time ALGS stock news. You can receive the latest news about Aligos Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About ALGS
Aligos Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics to address unmet medical needs in liver diseases and viral infections, including in the areas of chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronavirus infections such as, SARS-Co-V2, SARS-CoV, MERS-CoV, and other related infections. Its pipeline of drug candidates includes ALG-000184 for chronic HBV infection, ALG-055009 for MASH, ALG-097558 for coronavirus infections, and a portfolio of preclinical programs. ALG-000184 is a potential Capsid Assembly Modulator (CAM-E) for chronic HBV infection with enhanced pharmacologic properties. In the area of chronic HBV infection, its advanced drug candidate, ALG-000184, helps in disrupting the HBV lifecycle with viral suppression as well as reductions in viral antigens. Its ALG-055009 is an oral, small-molecule thyroid receptor beta agonist (THR-β) for the treatment of MASH.